# Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso

> **NCT03896724** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Oxford** · enrollment: 450 (actual)

## Conditions studied

- Malaria,Falciparum

## Interventions

- **BIOLOGICAL:** R21 adjuvanted with 25mcg Matrix-M
- **BIOLOGICAL:** Rabies Vaccine
- **BIOLOGICAL:** R21 adjuvanted with 50mcg Matrix-M

## Key facts

- **NCT ID:** NCT03896724
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-07
- **Primary completion:** 2023-07-07
- **Final completion:** 2023-07-07
- **Target enrollment:** 450 (ACTUAL)
- **Last updated:** 2025-07-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03896724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03896724, "Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03896724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*